This study is looking at the safety and effectiveness of a medicine called DefenCath to reduce infections in adults using a central venous catheter (CVC), a special tube used to give nutrition directly into the blood. It compares DefenCath to heparin, another medicine. The study is "double-blind," meaning neither the participants nor the researchers know who is getting which treatment to ensure fairness.

• Participants will be adults in the US and Türkiye, using a CVC for at least 7 days, and needing long-term nutrition therapy.
• Participants should be willing to follow study procedures, including training on how to use the medicines and keeping a daily diary.
• The study excludes those with certain health conditions or recent antibiotic use, and pregnant or lactating individuals.

This is a Phase 3 trial, meaning DefenCath has already shown promise in earlier research. Participants will help in understanding if DefenCath is a safer or better option for preventing infections in these situations. The study will involve keeping track of health and following specific guidelines for the duration of the research.